NCT03382795View on ClinicalTrials.gov

Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

PHASE2UnknownINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

January 3, 2018

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
EGFR Positive Non-small Cell Lung Cancer
Interventions
DRUG

EGFR

Gefitinib 250mg or Erlotinib 150mg medication, Once-Daily.

Trial Locations (8)

14068

Hallym University Sacred Heart Hospital, Anyang-si

35015

Chungnam National University Hospital, Daejeon

50612

Pusan National University Yangsan Hospital, Yangsan

58128

Chonnam National University Hwasun Hospital, Hwasun

03722

Yonsei University Severance Hospital, Seoul

05030

Konkuk University Medical Center, Seoul

05505

Asan Medical Center, Seoul

08308

Korea University Guro Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Chong Kun Dang Pharmaceutical Corp.

INDUSTRY

lead

Korea University Guro Hospital

OTHER